Home > Oncology > ESMO 2021 > Basic Science & Translational Research > Early ctDNA reduction in metastatic uveal melanoma correlates better with OS than RECIST response

Early ctDNA reduction in metastatic uveal melanoma correlates better with OS than RECIST response

Presented By
Dr Alexander Shoushtari, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
ESMO 2021
Trial
Phase 1/2, IMCgp100-202
An early reduction in circulating tumour (ct)DNA after second-line tebentafusp treatment in patients with metastatic uveal melanoma is associated with overall survival (OS), regardless of RECIST response, results from the IMCgp100-202 trial showed. Treatment with tebentafusp, a novel bispecific fusion protein that targets gp100 and activates T cells, has been shown to reduces the risk of death from metastatic uveal melanoma at 14 months by half, compared with available treatments [1]. However, OS was improved in patients regardless of RECIST best response, suggesting better surrogate efficacy endpoints are needed. In the IMCgp100-202 trial (NCT02570308), 127 patients with metastatic uveal melanoma were treated weekly with tebentafusp in second line. RECIST was assessed and serum samples (n=118) collected at baseline, week 5, and week 9 were analysed for ctD...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on